Cellectis Statistics
Total Valuation
Cellectis has a market cap or net worth of 111.54 million. The enterprise value is 78.52 million.
| Market Cap | 111.54M |
| Enterprise Value | 78.52M |
Important Dates
The next estimated earnings date is Monday, August 4, 2025.
| Earnings Date | Aug 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 72.29M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +57.25% |
| Shares Change (QoQ) | +0.06% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 39.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.04 |
| PB Ratio | 0.96 |
| P/TBV Ratio | 0.96 |
| P/FCF Ratio | 4.23 |
| P/OCF Ratio | 3.83 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.30 |
| EV / Sales | 1.36 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 2.98 |
Financial Position
The company has a current ratio of 1.67, with a Debt / Equity ratio of 0.83.
| Current Ratio | 1.67 |
| Quick Ratio | 0.94 |
| Debt / Equity | 0.83 |
| Debt / EBITDA | n/a |
| Debt / FCF | 3.65 |
| Interest Coverage | -7.09 |
Financial Efficiency
Return on equity (ROE) is -58.55% and return on invested capital (ROIC) is -16.23%.
| Return on Equity (ROE) | -58.55% |
| Return on Assets (ROA) | -9.19% |
| Return on Invested Capital (ROIC) | -16.23% |
| Return on Capital Employed (ROCE) | -26.22% |
| Revenue Per Employee | 249,986 |
| Profits Per Employee | -276,402 |
| Employee Count | 222 |
| Asset Turnover | 0.15 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -50.79% in the last 52 weeks. The beta is 3.28, so Cellectis's price volatility has been higher than the market average.
| Beta (5Y) | 3.28 |
| 52-Week Price Change | -50.79% |
| 50-Day Moving Average | 2.41 |
| 200-Day Moving Average | 9.64 |
| Relative Strength Index (RSI) | 31.57 |
| Average Volume (20 Days) | 424 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cellectis had revenue of 54.75 million and -60.53 million in losses. Loss per share was -0.62.
| Revenue | 54.75M |
| Gross Profit | 54.75M |
| Operating Income | -52.84M |
| Pretax Income | -60.27M |
| Net Income | -60.53M |
| EBITDA | -41.05M |
| EBIT | -52.84M |
| Loss Per Share | -0.62 |
Balance Sheet
The company has 127.64 million in cash and 96.23 million in debt, giving a net cash position of 31.41 million.
| Cash & Cash Equivalents | 127.64M |
| Total Debt | 96.23M |
| Net Cash | 31.41M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 116.20M |
| Book Value Per Share | 1.61 |
| Working Capital | 109.26M |
Cash Flow
In the last 12 months, operating cash flow was 29.14 million and capital expenditures -2.76 million, giving a free cash flow of 26.38 million.
| Operating Cash Flow | 29.14M |
| Capital Expenditures | -2.76M |
| Free Cash Flow | 26.38M |
| FCF Per Share | n/a |
Margins
Gross margin is 100.00%, with operating and profit margins of -96.52% and -110.57%.
| Gross Margin | 100.00% |
| Operating Margin | -96.52% |
| Pretax Margin | -110.09% |
| Profit Margin | -110.57% |
| EBITDA Margin | -74.98% |
| EBIT Margin | -96.52% |
| FCF Margin | 48.19% |
Dividends & Yields
Cellectis does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -57.25% |
| Shareholder Yield | n/a |
| Earnings Yield | -54.27% |
| FCF Yield | 23.65% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Cellectis has an Altman Z-Score of -0.95. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.95 |
| Piotroski F-Score | n/a |